Replies to post #114993 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Here is the link to Alfred Health Annual Report 2015-16

Alzheimer’s drug trial success
Early research results of Anavex 2-73, a drug which aims
to address the symptoms of dementia, are positive.
Trials at Caulfield Hospital are using Anavex, which, unlike
current medications, is the only drug designed to both relieve
symptoms and slow the disease’s progression.
The first phase of the trial began in December 2014 and the
next steps will involve further research with a larger group of
participants in 2017.

And from Who funds clinical trials?

Clinical trials are sponsored or funded by various organisations or individuals, including government departments and agencies, research groups, foundations, charities, and pharmaceutical, medical device and biotechnology companies.

K9uwa has previous answered the Kld2 on this topic here

To me this all provides a good indication, albeit not proof, that the A2-73 trials and extensions have so far been funded in large part outside of the Anavex accounts. It stands to reason that this will continue for the long awaited P2/3 Alzheimer's trial.

Perhaps someone can definitively disprove A2-73 Alzheimer's trials are largely funding by outside organisations, for example by showing us where in the Anavex accounts sufficient expenses to run the trials and extension appear?